NCT00089791View on ClinicalTrials.gov

A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis

PHASE3CompletedINTERVENTIONAL

Enrollment

7,808

Participants

Timeline

Start Date

August 1, 2004

Primary Completion Date

June 17, 2008

Study Completion Date

June 17, 2008

Conditions

Osteoporosis

Interventions

DRUG

placebo

Placebo administered by subcutaneous injection

DRUG

Denosumab

Denosumab 60 mg administered by subcutaneous injection

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY